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LETTER TO THE EDITOR

Convalescent Plasma: Promise
for COVID-19 Pandemic
Sir,
Severe acute respiratory syndrome coronavirus (SAR-CoV-2),
which is the cause of coronavirus disease (COVID-19) pandemic,
challenged scientiﬁc minds to search for new treatments.
Suggested therapies are in rapid development with questionable
eﬃcacy. We proposed that human convalescent plasma is a viable
option for prevention and treatment of COVID-19, where antibody
will be given to a susceptible person as passive antibody therapy;
and transferred immunoglobulin can confer protection from
weeks to months. It has been used for Ebola virus outbreak in 2014
and Middle-east respiratory syndrome coronavirus in 2015,1
SARS-CoV, H5N1 avian inﬂuenza, and H1N1 inﬂuenza. Many
patients received single dose infusion in the past with remarkable
improvement. Limited data from China, using convalescent
plasma for COVID19 pandemic, has shown clinical beneﬁt.2 Four
patients with COVID-19 received convalescent plasma, including
a pregnant woman, and recovered; however, larger studies are
required to investigate the eﬃcacy of convalescent plasma therapy.3
A case series from JAMA suggested drastic improvement in clinical
parameters.4 One of the explanations was that antibodies will
suppress viremia and limit infection rate. Five critically ill patients
with COVID-19 were treated with anti SARS-CoV-2 antibodies and
found with negative viral load. It was also suggested to give
plasma in the early stages of disease. Limited published data
showed no adverse events; hence, making it more worthy treatment option.

US Federal Drug Authority (FDA) announced a programme,
which will be operated in collaboration with the American Red
Cross and the National Blood Banking Community in the United
States.5 This programme will provide access to investigational
convalescent plasma for patients across the nation in acute care
facilities infected with SARS-CoV-2, the virus that causes
COVID-19, exhibiting severe or life-threatening COVID-19; or
those at high risk of progression to severe or life-threatening
disease. The convalescent plasma access programmes, led by
national initiative of physicians and investigators from 40 institutions in the United States, have self-organised to investigate the
use of convalescent plasma in the current COVID-19 pandemic.
These institutions are seeking to establish a national convalescent plasma programme to modify the course of disease. Plasma
obtained from those who have recovered from COVID-19 will be
given to the aﬀected ones in a hope that they will recover faster. It
is suggested as one of the treatments that scientists could
propose. Protocols are under development. Safety data collection is under consideration to include serious adverse events,
related to administration of convalescent plasma. Patients will
be best matched with data gathering including demographics,
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hospital stay, and survival to discharge. This approach will have
the potential to protect populations and will give a way forward to
study other investigational therapies.
We anticipate that recovered patients from COVID-19 will be
assessed clinically, including viral nucleic acid screening. Necessary regulatory permissions should be in place. Donated sera will
be pooled and used to treat individuals with early symptoms. If it is
established, it could allow many healthcare workers to maintain
their critical function. It could be used as a stopgap option amidst
pandemic. However, it is needed to pace up the eﬀorts by authorities to protect high risk individuals and consider its urgent preparation and the emergent use.
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